These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34440757)

  • 1. A Prognostic Role for Circulating microRNAs Involved in Macrophage Polarization in Advanced Non-Small Cell Lung Cancer.
    Monastirioti A; Papadaki C; Rounis K; Kalapanida D; Mavroudis D; Agelaki S
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Integrative Analysis Reveals the Association of
    Arora S; Singh P; Ahmad S; Ahmad T; Dohare R; Almatroodi SA; Alrumaihi F; Rahmani AH; Syed MA
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients.
    Kumar S; Sharawat SK; Ali A; Gaur V; Malik PS; Kumar S; Mohan A; Guleria R
    Curr Probl Cancer; 2020 Aug; 44(4):100540. PubMed ID: 32007320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High circulating miR-18a, miR-20a, and miR-92a expression correlates with poor prognosis in patients with non-small cell lung cancer.
    Xu X; Zhu S; Tao Z; Ye S
    Cancer Med; 2018 Jan; 7(1):21-31. PubMed ID: 29266846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab.
    Halvorsen AR; Sandhu V; Sprauten M; Flote VG; Kure EH; Brustugun OT; Helland Å
    Acta Oncol; 2018 Sep; 57(9):1225-1231. PubMed ID: 29683761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).
    Joerger M; Baty F; Früh M; Droege C; Stahel RA; Betticher DC; von Moos R; Ochsenbein A; Pless M; Gautschi O; Rothschild S; Brauchli P; Klingbiel D; Zappa F; Brutsche M
    Lung Cancer; 2014 Aug; 85(2):306-13. PubMed ID: 24928469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic Evaluation of Circulating miRNA Profile in
    Leonetti A; Capula M; Minari R; Mazzaschi G; Gregori A; El Hassouni B; Papini F; Bordi P; Verzè M; Avan A; Tiseo M; Giovannetti E
    Cells; 2021 Jun; 10(6):. PubMed ID: 34208765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Role of Circulating Exosomal miR-425-3p for the Response of NSCLC to Platinum-Based Chemotherapy.
    Yuwen D; Ma Y; Wang D; Gao J; Li X; Xue W; Fan M; Xu Q; Shen Y; Shu Y
    Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):163-173. PubMed ID: 30228154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating miR-30b and miR-30c predict erlotinib response in EGFR-mutated non-small cell lung cancer patients.
    Hojbjerg JA; Ebert EBF; Clement MS; Winther-Larsen A; Meldgaard P; Sorensen B
    Lung Cancer; 2019 Sep; 135():92-96. PubMed ID: 31447008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evaluation of microRNA expression profiling in non small cell lung cancer.
    Markou A; Sourvinou I; Vorkas PA; Yousef GM; Lianidou E
    Lung Cancer; 2013 Sep; 81(3):388-396. PubMed ID: 23756108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomal miR-126 as a circulating biomarker in non-small-cell lung cancer regulating cancer progression.
    Grimolizzi F; Monaco F; Leoni F; Bracci M; Staffolani S; Bersaglieri C; Gaetani S; Valentino M; Amati M; Rubini C; Saccucci F; Neuzil J; Tomasetti M; Santarelli L
    Sci Rep; 2017 Nov; 7(1):15277. PubMed ID: 29127370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spatial interaction and functional status of CD68
    Liu X; Zhang Z; Yuan J; Yu J; Chen D
    Front Immunol; 2024; 15():1396719. PubMed ID: 38799432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of Serum MicroRNAs in the Auxiliary Diagnosis of Non-Small Cell Lung Cancer.
    Shi GL; Chen Y; Sun Y; Yin YJ; Song CX
    Clin Lab; 2017 Jan; 63(1):133-140. PubMed ID: 28164492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer.
    Yang X; Zhang Q; Zhang M; Su W; Wang Z; Li Y; Zhang J; Beer DG; Yang S; Chen G
    Int J Biol Sci; 2019; 15(8):1712-1722. PubMed ID: 31360113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer.
    Halvorsen AR; Bjaanæs M; LeBlanc M; Holm AM; Bolstad N; Rubio L; Peñalver JC; Cervera J; Mojarrieta JC; López-Guerrero JA; Brustugun OT; Helland Å
    Oncotarget; 2016 Jun; 7(24):37250-37259. PubMed ID: 27191990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating microRNAs predict the response to anti-PD-1 therapy in non-small cell lung cancer.
    Fan J; Yin Z; Xu J; Wu F; Huang Q; Yang L; Jin Y; Yang G
    Genomics; 2020 Mar; 112(2):2063-2071. PubMed ID: 31786291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating miR-21-5p and miR-126-3p: diagnostic, prognostic value, and multivariate analysis in non-small-cell lung cancer.
    Soliman SE; Abdelaleem AH; Alhanafy AM; Ibrahem RAL; Elhaded ASA; Assar MFA
    Mol Biol Rep; 2021 Mar; 48(3):2543-2552. PubMed ID: 33837901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer.
    Wei J; Gao W; Zhu CJ; Liu YQ; Mei Z; Cheng T; Shu YQ
    Chin J Cancer; 2011 Jun; 30(6):407-14. PubMed ID: 21627863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating serum exosomal miR-20b-5p and miR-3187-5p as efficient diagnostic biomarkers for early-stage non-small cell lung cancer.
    Zhang ZJ; Song XG; Xie L; Wang KY; Tang YY; Yu M; Feng XD; Song XR
    Exp Biol Med (Maywood); 2020 Oct; 245(16):1428-1436. PubMed ID: 32741216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum miR-30c Level Predicted Cardiotoxicity in Non-small Cell Lung Cancer Patients Treated with Bevacizumab.
    Zhou F; Lu X; Zhang X
    Cardiovasc Toxicol; 2018 Jun; 18(3):284-289. PubMed ID: 29737469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.